biomega® was founded in 2000 on the premise of advancing innovative biotechnology to release the full nutritional and functional value of side streams from the salmon industry. Today, biomega® has a rich patent family of various technologies, with the continuous enzymatic hydrolysis process at its core. biomega® invests continuously in innovation through R&D to ensure best-in-class technology and respond to customers’ needs, including product development, traceability and sustainability.
In our modern biorefineries we turn food-grade fresh raw materials into premium ingredients. Sophisticated biorefining processes ensure careful separation of nutritional components. Local and fresh raw materials guarantee stable supply to our customers around the world.
The acquisition of biomega® by AMERRA Capital in 2017 has allowed the company to release its full growth potential. biomega® is now increasing its number of production facilities by building a new biorefinery in Hirtshals / Denmark entering into strategic partnerships with further raw material providers. Our technology is not only limited to salmon, but also includes other marine species such as cod, pelagic and mesopelagic, as well as chicken and other types of poultry and is part of the circular economy strategy.
biomega® aspires to become the leading partner for innovative high-quality ingredients to the health and nutrition industry.
Click on the links below for the latest inspection reports for biomega® Denmark
Control Report 2022
Control Report 2023
Control Report October 2023
